- Home
- KYTX vs FATE Comparison
KYTX vs FATE Comparison
Compare KYTX & FATE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KYTX
- FATE
- Stock Information
- Founded
- KYTX 2018
- FATE 2007
- Country
- KYTX United States
- FATE United States
- Employees
- KYTX N/A
- FATE N/A
- Industry
- KYTX
- FATE Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- KYTX
- FATE Health Care
- Exchange
- KYTX NYSE
- FATE Nasdaq
- Market Cap
- KYTX 125.2M
- FATE 108.2M
- IPO Year
- KYTX 2024
- FATE 2013
- Fundamental
- Price
- KYTX $1.93
- FATE $0.79
- Analyst Decision
- KYTX Buy
- FATE Hold
- Analyst Count
- KYTX 4
- FATE 9
- Target Price
- KYTX $19.00
- FATE $5.50
- AVG Volume (30 Days)
- KYTX 294.1K
- FATE 1.9M
- Earning Date
- KYTX 03-27-2025
- FATE 03-05-2025
- Dividend Yield
- KYTX N/A
- FATE N/A
- EPS Growth
- KYTX N/A
- FATE N/A
- EPS
- KYTX N/A
- FATE N/A
- Revenue
- KYTX N/A
- FATE $13,631,000.00
- Revenue This Year
- KYTX N/A
- FATE N/A
- Revenue Next Year
- KYTX N/A
- FATE N/A
- P/E Ratio
- KYTX N/A
- FATE N/A
- Revenue Growth
- KYTX N/A
- FATE N/A
- 52 Week Low
- KYTX $1.90
- FATE $0.76
- 52 Week High
- KYTX $25.84
- FATE $7.35
- Technical
- Relative Strength Index (RSI)
- KYTX 27.74
- FATE 33.50
- Support Level
- KYTX $2.20
- FATE $0.83
- Resistance Level
- KYTX $2.57
- FATE $0.96
- Average True Range (ATR)
- KYTX 0.19
- FATE 0.07
- MACD
- KYTX -0.02
- FATE 0.00
- Stochastic Oscillator
- KYTX 4.00
- FATE 11.15
About KYTX KYVERNA THERAPEUTICS INC
Kyverna Therapeutics Inc is a clinical-stage biopharmaceutical company. It is focused on developing cell therapies for patients suffering from autoimmune diseases. Its product KYV-101, is an autologous CD19 CAR T-cell product candidate made from an underlying chimeric antigen receptor, or CAR. It is also developing KYV-201, an allogeneic therapy containing the same CAR as KYV-101, to develop it in multiple autoimmune diseases.
About FATE Fate Therapeutics Inc.
Fate Therapeutics Inc is a clinical-stage biopharmaceutical company based in the United States. It is engaged in the development of programmed cellular immunotherapies for cancer and autoimmune disorders. The company's cell therapy pipeline is comprised of NK- and T-cell immuno-oncology programs, including off-the-shelf engineered product candidates derived from clonal master iPSC lines, and immuno-regulatory programs, including product candidates to prevent life-threatening complications in patients.